Author(s)

Zhuqing Sha

Affiliation(s)

Department of Neurology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China.

Corresponding Author

Zhuqing Sha

ABSTRACT

Topiramate is a broad-spectrum anti-epileptic drug (anti-epileptic drugs, AED) with multiple mechanisms of action, which is widely used in the treatment of various types of epilepsy and epilepsy syndromes. How to correctly select effective AEDs and balance the relationship between drug efficacy and adverse reactions has always been a key issue in clinical practice. This article describes the research progress of topiramate's clinical application, mechanism and safety management, including cognitive impairment, nephrolithiasis and sudomotor dysfunction. This article reviews the research progress on the clinical application and safety management of topiramate, including cognitive impairment, kidney stones and sudomotor dysfunction.

KEYWORDS

Topiramate; Epilepsy; Clinical application; Safety management.

CITE THIS PAPER

Zhuqing Sha. Research progress on clinical application and safety management of topiramate. World Journal of Clinical Sciences. 2023, 1(1): 1-6.

REFERENCES

[1] Lyseng-Williamson KA, Yang LP. Spotlight on topiramate in epilepsy. CNS Drugs, 2008, 22(2): 171-174.

[2] Bresnahan R, Hounsome J, JetteN. Topiramate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev, 2019, 10(10): CD001417.

[3] Liu J, Wang LN, Wang YP. Topiramate for juvenile myoclonicepilepsy. Cochrane Database Syst Rev, 2019, 1(1): CD010008.

[4] Song JM, Hahn J, Kim SH. Efficacy of Treatments for Infantile Spasms: A Systematic review. Clin Neuropharmacol, 2017, 40(2): 63-84.

[5] Knupp KG, Wirrell EC. Treatment Strategies for Dravet Syndrome. CNS Drugs, 2018, 32(4): 335-350

[6] Montouris G, Aboumatar S, Burdette D, et al. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients. Epilepsy Behav, 2020, 110: 107146

[7] Kr?ll-Seger J, Portilla P, Dulac O. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics, 2006, 37(6): 325-329

[8] SachdeoRC, GlauserTA, Ritter F. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology, 1999, 52(9): 1882-1887

[9] Xu Lan, Hong Zhen, Wu Xunyi. Ion channels and epilepsy. Chinese Clinical Neuroscience, 2009, 17(4): 436-443

[10] Musto E, Gardella E, M?ller RS. Recent advances in treatment of epilepsy-related sodium channelopathies. Eur J Paediatr Neurol, 2020, 24: 123-128

[11] Rajakulendran S, Hanna MG. The Role of Calcium Channels in Epilepsy. Cold Spring Harb Perspect Med, 2016, 6(1): a022723

[12] Barker-Haliski M, White HS. Glutamatergic Mechanisms Associated with Seizures and Epilepsy. Cold Spring Harb Perspect Med, 2015, 5(8): a022863

[13] Hernandez CC, Macdonald RL. A structural look at GABAA receptor mutations linked to epilepsy syndromes. Brain Res, 2019, 1714: 234-247.

[14] Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother, 2006, 7(6): 811-823.

[15] Verrotti A, Scaparrotta A, Agostinelli S. Topiramate-induced weight loss: a review. Epilepsy Res, 2011, 95(3): 189-199.

[16] SinhaA, Oo P, Asghar MU. Type II Renal Tubular Acidosis Secondary to Topiramate: A Review. Cureus, 2018, 10(11): e3635.

[17] Jia Jianping, Chen Shengdi. Neurology. 8th Edition. Beijing: People's Medical Publishing House, 2018.

[18] Witt JA, Helmstaedter C. Cognition in epilepsy: current clinical issues of interest. CurrOpin Neurol, 2017, 30(2):174-179.

[19] Leeman-Markowski BA, Schachter SC. Treatment of Cognitive Deficits in Epilepsy. Neurol Clin, 2016, 34(1): 183-204.

[20] Nickels KC, Zaccariello MJ, Hamiwka LD. Cognitive and neurodevelopmental comorbidities in pediatric epilepsy. Nat Rev Neurol, 2016, 12(8): 465-476.

[21] Mula M. Topiramate and cognitive impairment: evidence and clinical implications. TherAdv DrugSaf, 2012, 3(6): 279-289.

[22] Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. TherAdvNeurol Disord, 2011, 4(6): 385-407.

[23] Lu Y, Yu W, Wang X. Efficacy of topiramate in adult patients with symptomatic epilepsy: an open-label, long-term, retrospective observation. CNS Drugs, 2009, 23(4): 351-359.

[24] Zhang L, Huang J, Zhuang JH. Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. J Int Med Res, 2011, 39(2): 408-415.

[25] Loring DW, Williamson DJ, Meador KJ. Topiramate dose effects on cognition: a randomized double blind study. Neurology, 2011, 76(2): 131-137.

[26] Stefan H, Hubbertz L, Peglau I. Epilepsy outcomes in elderly treated with topiramate. ActaNeurol cand, 2008, 118(3): 164- 174.

[27] Quan Shuyan, Zhang Lingli, Wang Ling. Systematic review and Meta-analysis of the effects of topiramate on children's cognitive function. Chinese Journal of Evidence-Based Pediatrics, 2015, 10(1): 57-61.

[28] Thompson PJ, Baxendale SA, Duncan JS. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry, 2000, 69(5): 636–641.

[29] Jung DE, Kim HD, Hur YJ. Topiramate on the quality of life in childhood epilepsy. Brain Dev, 2011, 33(9): 707-712.

[30] Callisto SP, Illamola SM, Birnbaum AK. Severity of topiramate-related working memory impairment is modulated by plasma concentration and working memory capacity. J Clin Pharmacol, 2020Apr 16. doi: 10.1002/jcph.1611.

[31] Barkley CM, Hu Z, Fieberg AM. Individual Differences in Working Memory Capacity Predict Topiramate-Related Cognitive Deficits. J Clin Psychopharmacol, 2018, 38(5): 481-488.

[32] Witt JA, Hel mstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs?. Expert Opin Pharmacother, 2017, 18(6): 551-554.

[33] Yam KM, Yau ML, Fung EL. Nephrolithiasis associated with the use of topiramate in children. Hong Kong MedJ, 2017, 23(6): 654-655.

[34] Xi'an Janssen Pharmaceutical Co., Ltd. Product Instructions for Topiramate Tablets. Beijing: 20200302.

[35] Mahmoud AA, Rizk T, El-Bakri NK. Incidence of kidney stones with topiramate treatment in pediatric patients. Epilepsia, 2011, 52(10): 1890-1893.

[36] Corbin Bush N, Twombley K, Ahn J. Prevalence and spot urine risk factors for renal stones in children taking topiramate. J PediatrUrol, 2013, 9(6 PtA): 884-889.

[37] Shen AL, Lin HL, Tseng YF. Topiramate may not increase risk of urolithiasis: A nationwide population-based cohort study. Seizure, 2015, 29: 86-89.

[38] Lamb EJ, Stevens PE, NashefL. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem, 2004, 41(Pt 2): 166-169.

[39] Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol, 2009, 68(5): 655-661.

[40] Luo Xiaobo, Wu Jianhong. Topiramate-induced recurrent urinary calculi case report and literature review. Medical Herald, 2011, 30(10): 1385-1388.

[41] Ma Lei, Huang Yuangui, Deng Yanchun. Multicenter study and risk factor analysis of topiramate-induced sweating disorder. Chinese Journal of Neuropsychiatry, 2008, 34(10): 587-590.

[42] Zeng Shaohui, Lei Zhaobao. Adverse reaction of topiramate and its prevention and treatment. Chinese Pharmacist, 2009, 12(5): 668-670.

[43] Huang Shaoping, Guo Yale, He Guangzu. Clinical analysis of 42 cases of epilepsy-like summer fever in children induced by topiramate Chinese Journal of Practical Pediatrics, 2004, 19(10): 623-624.

[44] Wang Tao. Literature analysis on adverse reactions of topiramate. Chinese Journal of Hospital Pharmacy, 2008, 28(14): 1230-1231.